Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Immune Based Ther Vaccines ; 3(1): 2, 2005 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-15842730

RESUMO

BACKGROUND: Human papillomaviruses (HPV) are the most common sexually transmitted viruses. Infection of the cervical epithelium by HPVs can lead to the development of cervical cancer. Recent advances in vaccine research have shown that immunization with papillomavirus-like particles (VLPs) containing the major structural viral protein, L1 from HPV 16 can provide protection from the establishment of a chronic HPV 16 infection and related cervical intraepithelial neoplasia (CIN) in baseline HPV 16 naive women. METHODS: To better understand the quantitative and qualitative effects of aluminum adjuvant on the immunogenic properties of an HPV 6, 11, 16 and 18L1 VLP vaccine, we used an HPV-specific, antibody isotyping assay and a competitive immunoassay that measures antibodies to neutralizing epitopes to profile sera from rhesus macaques immunized with the HPV L1 VLP vaccine formulated with or without aluminum adjuvant. RESULTS: Immunization with VLPs formulated with the aluminum adjuvant elicited a significantly stronger immune response with higher peak antibody titers both at four weeks post vaccination (12.7 to 41.9-fold higher) as well as in the persistent phase at week 52 (4.3 to 26.7-fold higher) than that of VLPs alone. Furthermore, the aluminum adjuvant formulated HPV VLP vaccine elicited a predominantly T helper type 2 response, with high levels of IgG1 and IgG4 and low levels of IgG2. The vaccine also elicited high levels of serum IgA, which may be important in providing mucosal immunity to impart protection in the anogenital tract. CONCLUSION: These results show that the HPV 6, 11, 16 and 18 L1-VLP vaccine formulated with Merck aluminum adjuvant elicits a robust and durable immune response and holds promise as a vaccine for preventing cervical cancer.

2.
J Med Microbiol ; 52(Pt 11): 989-998, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14532344

RESUMO

Staphylococcus epidermidis is a significant cause of nosocomial disease. However, the taxonomy of this pathogen, particularly at subspecies level, is unclear. A multilocus sequence typing (MLST) scheme has therefore been investigated as a tool to elucidate taxonomic relationships within this group, based on genetic relatedness. DNA sequences for internal fragments of seven housekeeping genes were compared in 47 geographically and temporally diverse S. epidermidis isolates that were obtained from clinical infections. Twenty-three different allelic profiles were detected; 17 of these were represented by single strains and the largest profile group contained 17 isolates. Diversity of the same collection of isolates was investigated by using PFGE of SmaI-digested genomic DNA to test the discrimination and validity of the MLST approach. Isolates within the largest profile group were resolved into four distinct PFGE clusters on the basis of their SmaI digest patterns. Isolates within other profile groups that contained multiple isolates had matching PFGE SmaI patterns within each group. It appears that MLST is an effective method for grouping S. epidermidis strains at the subspecies level; however, it is not as discriminatory as it has been for other species for which MLST schemes have been established and, used alone, would not be a useful method for epidemiological studies. In addition, it was demonstrated that this method was effective for confirming the identity of S. epidermidis CoNS (coagulase-negative) isolates.


Assuntos
Técnicas de Tipagem Bacteriana/métodos , Staphylococcus epidermidis/classificação , Sequência de Bases , Eletroforese em Gel de Campo Pulsado , Resistência a Meticilina , Dados de Sequência Molecular , Staphylococcus epidermidis/efeitos dos fármacos , Staphylococcus epidermidis/genética
3.
J Virol Methods ; 108(1): 83-90, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12565157

RESUMO

Human papillomavirus (HPV) DNA replication requires functional HPV early (E) proteins E1 and E2. To determine the biological activity of HPV 16 E1 and E2 mutant proteins under consideration as vaccine candidates, we developed a sensitive real time PCR assay that monitors HPV origin-of-replication-driven DNA synthesis. The assay was used to determine the DNA replicative functions of highly-expressed, codon-optimized HPV 16 E1 and E2 wild type and mutant proteins in transient transfections. Under the assay conditions, the HPV 16 E1 mutant (W439R, G482D) did not support HPV origin-driven DNA synthesis. In contrast, however, an HPV 16 E2 mutant bearing an E39A substitution, reported previously to be severely compromised for DNA replication, was found to be reduced only two-fold in activity and, therefore, considered not sufficiently inactivated for use in vaccines that depend on endogenous protein expression.


Assuntos
Replicação do DNA/genética , Proteínas de Ligação a DNA , Proteínas Oncogênicas Virais/genética , Proteínas Oncogênicas Virais/metabolismo , Papillomaviridae/genética , Papillomaviridae/metabolismo , Substituição de Aminoácidos , Sequência de Bases , Linhagem Celular , Códon/genética , DNA Viral/biossíntese , DNA Viral/genética , Humanos , Proteínas Oncogênicas Virais/imunologia , Papillomaviridae/imunologia , Plasmídeos/genética , Mutação Puntual , Reação em Cadeia da Polimerase , Vacinas Virais/genética , Vacinas Virais/imunologia , Virologia/métodos
4.
Infect Immun ; 74(4): 2215-23, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16552052

RESUMO

Staphylococcus aureus is a major cause of nosocomial infections worldwide, and the rate of resistance to clinically relevant antibiotics, such as methicillin, is increasing; furthermore, there has been an increase in the number of methicillin-resistant S. aureus community-acquired infections. Effective treatment and prevention strategies are urgently needed. We investigated the potential of the S. aureus surface protein iron surface determinant B (IsdB) as a prophylactic vaccine against S. aureus infection. IsdB is an iron-sequestering protein that is conserved in diverse S. aureus clinical isolates, both methicillin resistant and methicillin sensitive, and it is expressed on the surface of all isolates tested. The vaccine was highly immunogenic in mice when it was formulated with amorphous aluminum hydroxyphosphate sulfate adjuvant, and the resulting antibody responses were associated with reproducible and significant protection in animal models of infection. The specificity of the protective immune responses in mice was demonstrated by using an S. aureus strain deficient for IsdB and HarA, a protein with a high level of identity to IsdB. We also demonstrated that IsdB is highly immunogenic in rhesus macaques, inducing a more-than-fivefold increase in antibody titers after a single immunization. Based on the data presented here, IsdB has excellent prospects for use as a vaccine against S. aureus disease in humans.


Assuntos
Anticorpos Antibacterianos/biossíntese , Antígenos de Bactérias/imunologia , Proteínas de Transporte de Cátions/imunologia , Macaca mulatta/imunologia , Sepse/imunologia , Infecções Estafilocócicas/imunologia , Vacinas Antiestafilocócicas/imunologia , Staphylococcus aureus/imunologia , Animais , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/química , Proteínas de Transporte de Cátions/administração & dosagem , Proteínas de Transporte de Cátions/química , Modelos Animais de Doenças , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos ICR , Sepse/mortalidade , Sepse/prevenção & controle , Homologia de Sequência de Aminoácidos , Infecções Estafilocócicas/mortalidade , Infecções Estafilocócicas/prevenção & controle , Vacinas Antiestafilocócicas/administração & dosagem , Staphylococcus aureus/isolamento & purificação , Taxa de Sobrevida
5.
Vaccine ; 21(13-14): 1539-47, 2003 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-12615451

RESUMO

There have been numerous studies to assess the immunogenicity of candidate therapeutic and prophylactic vaccines for human papillomavirus (HPV), but few of them have directly compared different vaccines in an immunologically relevant animal system. In the present study, several vaccine delivery systems (VLPs, chimeric VLPs, plasmid DNA, and a replication incompetent adenoviral vector) expressing HPV16L1 were evaluated for their ability to induce HPV16L1 VLP-specific humoral immune responses, including neutralizing antibodies, and cell-mediated immune responses in rhesus macaques. Monkeys immunized with HPV16L1 VLPs mounted a potent humoral response with strongly neutralizing antibodies and a strong L1-specific Th2 response as measured by IL-4 production by CD4+ T cells. Monkeys immunized with plasmid DNA or an adenoviral vector expressing HPV16L1 showed strong Th1/Tc1 responses as measured by IFN-gamma production by CD4+ and/or CD8+ T cells and potent humoral responses, but only weakly neutralizing antibodies. These data demonstrate that the nature of the immune response against HPV16L1 is dramatically different when it is introduced via different delivery systems. Additionally, these findings support the notion that an HPV16L1 VLP-based vaccine will induce the strongly neutralizing antibodies necessary for effective prophylaxis.


Assuntos
Proteínas do Capsídeo , Proteínas Oncogênicas Virais/imunologia , Papillomaviridae/imunologia , Vacinas Virais/administração & dosagem , Vacinas Virais/imunologia , Vírion/imunologia , Adenoviridae/genética , Animais , Anticorpos Antivirais/sangue , Imunização , Interferon gama/biossíntese , Interleucina-4/biossíntese , Macaca mulatta , Linfócitos T/imunologia , Vacinas de DNA/imunologia
6.
J Gen Virol ; 84(Pt 6): 1493-1497, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12771418

RESUMO

The epitope for a human papillomavirus (HPV) type 6 conformation-dependent, neutralizing monoclonal antibody (mAb) was partially mapped using HPV L1 recombinant virus-like particles (VLPs). The mAb H6.J54 is cross-reactive with the closely related HPV types 6 and 11. By making HPV-6-like amino acid substitutions in the cottontail rabbit papillomavirus (CRPV) major capsid protein L1, we were able to transfer H6.J54 binding activity into a CRPV/HPV-6 hybrid L1 protein. Full binding activity was achieved with only nine amino acid changes and identified a region centred on the HPV-6 residues 49-54. This region has previously been shown to be a critical part of HPV-6 type-specific epitopes. Fine mapping of the region by scanning a series of alanine substitution mutations showed that in HPV-6 VLPs this type-common epitope overlaps HPV-6 type-specific epitopes.


Assuntos
Antígenos Virais , Papillomaviridae/imunologia , Sequência de Aminoácidos , Substituição de Aminoácidos , Anticorpos Monoclonais , Antígenos Virais/química , Antígenos Virais/genética , Reações Cruzadas , Mapeamento de Epitopos , Epitopos/química , Epitopos/genética , Humanos , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Papillomaviridae/genética , Conformação Proteica , Proteínas Virais/química , Proteínas Virais/genética , Proteínas Virais/imunologia
7.
Antimicrob Agents Chemother ; 47(9): 2740-8, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12936968

RESUMO

Staphylococcal infections associated with catheter and prosthetic implants are difficult to eradicate and often lead to chronic infections. Development of novel antibacterial therapies requires simple, reliable, and relevant models for infection. Using bioluminescent Staphylococcus aureus, we have adapted the existing foreign-body and deep-wound mouse models of staphylococcal infection to allow real-time monitoring of the bacterial colonization of catheters or tissues. This approach also enables kinetic measurements of bacterial growth and clearance in each infected animal. Persistence of infection was observed throughout the course of the study until termination of the experiment at day 16 in a deep-wound model and day 21 in the foreign-body model, providing sufficient time to test the effects of antibacterial compounds. The usefulness of both animal models was assessed by using linezolid as a test compound and comparing bioluminescent measurements to bacterial counts. In the foreign-body model, a three-dose antibiotic regimen (2, 5, and 24 h after infection) resulted in a decrease in both luminescence and bacterial counts recovered from the implant compared to those of the mock-treated infected mice. In addition, linezolid treatment prevented the formation of subcutaneous abscesses, although it did not completely resolve the infection. In the thigh model, the same treatment regimen resulted in complete resolution of the luminescent signal, which correlated with clearance of the bacteria from the thighs.


Assuntos
Corpos Estranhos/microbiologia , Infecções Estafilocócicas/microbiologia , Infecção dos Ferimentos/microbiologia , Abscesso/microbiologia , Acetamidas/uso terapêutico , Animais , Antibacterianos/uso terapêutico , Cateterismo , Contagem de Colônia Microbiana , Relação Dose-Resposta a Droga , Feminino , Corpos Estranhos/tratamento farmacológico , Corpos Estranhos/patologia , Linezolida , Medições Luminescentes , Camundongos , Camundongos Endogâmicos BALB C , Músculo Esquelético/patologia , Oxazolidinonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus aureus/crescimento & desenvolvimento , Staphylococcus aureus/metabolismo , Coxa da Perna/patologia , Fatores de Tempo , Infecção dos Ferimentos/tratamento farmacológico , Infecção dos Ferimentos/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA